there is only the commerical launch of 2 new fda approved drugs in 1H..... oh, and over 100M in cash to leverage a new deal... but thats all really.
solid days on high volume and holding over 50 and 100 day Moving averages. (plus the hard bounce off those averages last week, i think, at about 10.40. good overall techs, as well as story unfolding....
this qtr report in Feb. I anticipate news rolling out commercial production of Citr., with some timing details, and some followup of Triferic, with more general info on timing of rollout. We may get a surprise too, with a deal of liscensing or rumored purchase of a drug from another company? (now that they have cash to negiotiate)
la la long.
Do the work....
Rockwell Receives $20MM Upfront Cash; $15MM Equity Investment; $10MM in Milestone Payments Tied to Manufacturing Expansion
WIXOM, Mich., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it has signed an exclusive agreement with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (NYSE:BAX), to commercialize Rockwell's hemodialysis concentrate product line in the U.S. and in select overseas markets.
Under the terms of the agreement, Baxter will become the exclusive distributor of Rockwell's hemodialysis concentrate and ancillary products in the U.S. and selected foreign countries for an initial term of 10 years. Baxter can extend the agreement for two additional 5-year terms upon meeting certain sales targets, coupled with a $7.5 million payment related to the first extension. Baxter will purchase products from Rockwell at a pre-determined gross margin-based price per unit and is required to meet minimum annual purchase levels in order to retain their exclusive rights. Baxter will leverage Rockwell's unique distribution operations in order to provide specialized customer and delivery service for concentrates, covering Rockwell's costs for these services. Rockwell will retain sales, marketing and distribution rights for its hemodialysis concentrate products in certain foreign countries in which it has an established commercial presence.
i predict a modest short cover, which will be good. but the negative types want desperately to be right, so we'll still have a big short position going forward, just slightly less. the stock clearly behaviors weird when good news comes out - so a ton of traders love to play games here.
look for a new base to form over the next few months, If we can hold 38-40. chart pattern over the past 5 and 10 years have been very predictable for the cycle of washing out the stock, basing, than another climb cycle
just look at Nov. price chart, right before committee approval in early November...... exact same thing happening now. great news, stock price totally manipulated.
Apps. new stock symbol for Mandalay digital (mndl). exciting merger pending.... i own the stock.
recall the bear attack a few months ago before Adcom. looks like we might see the exact same play out this week, designed to mute any positive news thats pending. no big surprise here...
One of the biggest positives with new issue (the bankers wanted it before fda approval to make more money...)
Is now their balance sheet is prestine. this puts them in much better negiotiating position with other companies be it an aquisition, partnership, manufactoring contracts etc. rock is just better off in every way with strong balance sheet.